These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 36383914)
1. The Efficacy and Safety of Adjuvant Lomustine to Chemotherapy for Recurrent Glioblastoma: A Meta-analysis of Randomized Controlled Studies. Fu X; Shi D; Feng Y Clin Neuropharmacol; 2022 Nov-Dec 01; 45(6):162-167. PubMed ID: 36383914 [TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenic therapy for high-grade glioma. Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778 [TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of radiotherapy with adjuvant temozolomide for glioblastoma: A meta-analysis of randomized controlled studies. Wang Y; Feng Y Clin Neurol Neurosurg; 2020 Sep; 196():105890. PubMed ID: 32623215 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant Temozolomide for the Treatment of Glioblastoma: A Meta-analysis of Randomized Controlled Studies. Zhao Y; Wu J; Shi L Clin Neuropharmacol; 2021 Jul-Aug 01; 44(4):132-137. PubMed ID: 34039842 [TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic therapy for high-grade glioma. Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542 [TBL] [Abstract][Full Text] [Related]
7. The Efficacy of Adjuvant Chloroquine for Glioblastoma: A Meta-Analysis of Randomized Controlled Studies. Wei H; Jiang Z J Neurol Surg B Skull Base; 2022 Apr; 83(2):210-214. PubMed ID: 35433185 [No Abstract] [Full Text] [Related]
8. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291 [TBL] [Abstract][Full Text] [Related]
9. Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma. Duerinck J; Du Four S; Bouttens F; Andre C; Verschaeve V; Van Fraeyenhove F; Chaskis C; D'Haene N; Le Mercier M; Rogiers A; Michotte A; Salmon I; Neyns B J Neurooncol; 2018 Jan; 136(1):115-125. PubMed ID: 28988341 [TBL] [Abstract][Full Text] [Related]
10. Anti-epidermal growth factor receptor therapy for glioblastoma in adults. Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825 [TBL] [Abstract][Full Text] [Related]
11. Bevacizumab for recurrent glioblastoma: a systematic review and meta-analysis. Zhang T; Xin Q; Kang JM Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6480-6491. PubMed ID: 34787852 [TBL] [Abstract][Full Text] [Related]
12. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. Wick W; Puduvalli VK; Chamberlain MC; van den Bent MJ; Carpentier AF; Cher LM; Mason W; Weller M; Hong S; Musib L; Liepa AM; Thornton DE; Fine HA J Clin Oncol; 2010 Mar; 28(7):1168-74. PubMed ID: 20124186 [TBL] [Abstract][Full Text] [Related]
13. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Batchelor TT; Mulholland P; Neyns B; Nabors LB; Campone M; Wick A; Mason W; Mikkelsen T; Phuphanich S; Ashby LS; Degroot J; Gattamaneni R; Cher L; Rosenthal M; Payer F; Jürgensmeier JM; Jain RK; Sorensen AG; Xu J; Liu Q; van den Bent M J Clin Oncol; 2013 Sep; 31(26):3212-8. PubMed ID: 23940216 [TBL] [Abstract][Full Text] [Related]
14. The Efficacy of Dendritic Cell Vaccine for Newly Diagnosed Glioblastoma: A Meta-analysis of Randomized Controlled Studies. Tan L; Peng J; Liu P; Wu Q Clin Neuropharmacol; 2021 Nov-Dec 01; 44(6):216-221. PubMed ID: 34767325 [TBL] [Abstract][Full Text] [Related]
15. Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. Rahman R; Hempfling K; Norden AD; Reardon DA; Nayak L; Rinne ML; Beroukhim R; Doherty L; Ruland S; Rai A; Rifenburg J; LaFrankie D; Alexander BM; Huang RY; Wen PY; Lee EQ Neuro Oncol; 2014 Nov; 16(11):1523-9. PubMed ID: 24958095 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial. Beije N; Kraan J; Taal W; van der Holt B; Oosterkamp HM; Walenkamp AM; Beerepoot L; Hanse M; van Linde ME; Otten A; Vernhout RM; de Vos FY; Gratama JW; Sleijfer S; van den Bent MJ Br J Cancer; 2015 Jul; 113(2):226-31. PubMed ID: 26042933 [TBL] [Abstract][Full Text] [Related]
17. How did lomustine become standard of care in recurrent glioblastoma? Weller M; Le Rhun E Cancer Treat Rev; 2020 Jul; 87():102029. PubMed ID: 32408220 [TBL] [Abstract][Full Text] [Related]